(Q54523612)

30 May 2018

title

Peptichemio induction therapy in myelomatosis. (English)

1 reference

30 May 2018

author

Giampaolo Merlini

1

1 reference

30 May 2018

author name string

P G Gobbi

2

1 reference

30 May 2018

A Riccardi

3

1 reference

30 May 2018

G Riva

4

1 reference

30 May 2018

C Sardi

5

1 reference

30 May 2018

S Perugini

6

1 reference

30 May 2018

publication date

1 January 1982

1 reference

30 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

30 May 2018

volume

8

1 reference

30 May 2018

issue

1

1 reference

30 May 2018

page(s)

9-16

1 reference

30 May 2018

https://scigraph.springernature.com/pub.10.1007/bf00292864

exact match

0 references

cites work

Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood. 1968;31(1):1-10

1 reference

12 December 2020

Plasma cell leukemia (PCL): A report on 15 patients

1 reference

12 December 2020

Cytokinetic changes in two cases of plasma leukemia treated with a multipeptide derivative of m-[di(2-chloroethyl)amino]-L-phenylalanine (Peptichemio)

1 reference

12 December 2020

Myelomatosis: comparison of melphalan and cyclophosphamide therapy

1 reference

12 December 2020

Treatment of multiple myeloma with vincristine

1 reference

12 December 2020

MELPHALAN THERAPY IN MYELOMATOSIS.

1 reference

12 December 2020

Procarbazine (NSC-77213) and multiple myeloma.

1 reference

12 December 2020

Immunochemical classes of myelomatosis. Including data from a therapeutic trial conducted by a Medical Research Council working party

1 reference

12 December 2020

MULTIPLE MYELOMA. II. ANALYSIS OF CYCLOPHOSPHAMIDE THERAPY IN 165 PATIENTS

1 reference

12 December 2020

Treatment of plasma cell myeloma with cytotoxic agents

1 reference

12 December 2020

Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics

1 reference

12 December 2020

Combination chemotherapy of multiple myeloma with Alkeran, Cytoxan, vincristine, prednisone, and BCNU

1 reference

12 December 2020

Nitrosoureas in multiple myeloma

1 reference

12 December 2020

Combination therapy for multiple myeloma

1 reference

12 December 2020

The Treatment of Plasma Cell Myeloma

1 reference

12 December 2020

Leukemic form of immunocytic dyscrasia (plasma cell leukemia). A study of ten cases and a review of the literature

1 reference

12 December 2020

Urinary light-chain excretionin myeloma and other disorders--an evaluation of the Bence-Jones test

1 reference

12 December 2020

Peptichemio in the therapy of malignancies (phase-I-study). The evaluation committee

1 reference

12 December 2020

DNA-damage in human cells treated with the closely related alkylating agents peptichemio, m-L-sarcolysin and melphalan

1 reference

12 December 2020

A phase II clinical trial of peptichemio. Clinical screening cooperative group of European Organisation on Research on Treatment of Cancer (E.O.R.T.C)

1 reference

12 December 2020

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

12 December 2020

A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients.

1 reference

12 December 2020

Multiple myeloma: quantitative staging and assessment of response with a programmable pocket calculator

1 reference

12 December 2020

Proposed guidelines for protocol studies. II. Plasma cell myeloma. Prepared by a Committee of the Chronic Leukemia--Myeloma Task Force, National Cancer Institute

1 reference

12 December 2020

Adriamycin (NSC-123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00292864

1 reference

30 May 2018

1 reference

30 May 2018